Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data

G. Kafatos, D. Niepel, K. Lowe, S. Jenkins-Anderson, H. Westhead, T. Garawin, Z. Traugottová, A. Bilalis, E. Molnar, J. Timar, E. Toth, N. Gouvas, G. Papaxoinis, S. Murray, N. Mokhtar, H. Vosmikova, P. Fabian, A. Skalova, P. Wójcik, A....

. 2017 ; 11 (9) : 751-760. [pub] 20170727

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, metaanalýza, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028771
E-zdroje Online Plný text

NLK PubMed Central od 2015 do Před 1 rokem
ProQuest Central od 2007-06-01 do 2021-01-31
Health & Medicine (ProQuest) od 2007-06-01 do 2021-01-31
Public Health Database (ProQuest) od 2007-06-01 do 2021-01-31

Odkazy

PubMed 28747067
DOI 10.2217/bmm-2016-0358
Knihovny.cz E-zdroje

AIM: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. MATERIALS & METHODS: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses. RESULTS: The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8-48.5%); ranging from 33.7% (95% CI: 28.4-39.3%) to 54.1% (95% CI: 51.7-56.5%) between sources. CONCLUSION: The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028771
003      
CZ-PrNML
005      
20190819121331.0
007      
ta
008      
190813s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/bmm-2016-0358 $2 doi
035    __
$a (PubMed)28747067
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kafatos, George $u Amgen Ltd, Uxbridge, UK.
245    10
$a RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data / $c G. Kafatos, D. Niepel, K. Lowe, S. Jenkins-Anderson, H. Westhead, T. Garawin, Z. Traugottová, A. Bilalis, E. Molnar, J. Timar, E. Toth, N. Gouvas, G. Papaxoinis, S. Murray, N. Mokhtar, H. Vosmikova, P. Fabian, A. Skalova, P. Wójcik, A. Tysarowski, M. Barugel, JH. van Krieken, J. Trojan,
520    9_
$a AIM: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. MATERIALS & METHODS: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses. RESULTS: The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8-48.5%); ranging from 33.7% (95% CI: 28.4-39.3%) to 54.1% (95% CI: 51.7-56.5%) between sources. CONCLUSION: The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research.
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a kolorektální nádory $x epidemiologie $x mortalita $x patologie $7 D015179
650    _2
$a exony $7 D005091
650    _2
$a lidé $7 D006801
650    _2
$a mutace $7 D009154
650    _2
$a prevalence $7 D015995
650    _2
$a protoonkogenní proteiny B-raf $x genetika $7 D048493
650    _2
$a protoonkogenní proteiny p21(ras) $x genetika $7 D016283
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Niepel, Daniela $u Amgen GmbH, Vienna, Austria.
700    1_
$a Lowe, Kimberley $u Amgen Inc., Thousand Oaks, CA, USA.
700    1_
$a Jenkins-Anderson, Sophie $u Adelphi Research (Global), Manchester, UK.
700    1_
$a Westhead, Hal $u Adelphi Research (Global), Manchester, UK.
700    1_
$a Garawin, Tamer $u Amgen Inc., Thousand Oaks, CA, USA.
700    1_
$a Traugottová, Zuzana $u Amgen s.r.o., Prague, Czech Republic.
700    1_
$a Bilalis, Antonios $u Amgen Hellas EPE, Athens, Greece.
700    1_
$a Molnar, Edit $u Amgen Kft, Budapest, Hungary.
700    1_
$a Timar, Jozsef $u Semmelweis Medical University, Budapest, Hungary.
700    1_
$a Toth, Erika $u National Institute of Oncology, Budapest, Hungary.
700    1_
$a Gouvas, Nikolaos $u Gastrointestinal Cancer Study Group, Heraklion, Crete, Greece.
700    1_
$a Papaxoinis, George $u Hellenic Cooperative Oncology Group, University of Athens, Athens, Greece.
700    1_
$a Murray, Samuel $u Biomarker Solutions, London, UK.
700    1_
$a Mokhtar, Nadia $u National Cancer Institute, Cairo University, Cairo, Egypt.
700    1_
$a Vosmikova, Hana $u University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Fabian, Pavel $u Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Skalova, Alena $u Bioptická laboratoř, Plzeň, Czech Republic.
700    1_
$a Wójcik, Piotr $u Oncogene Diagnostics Sp.z.o.o., Krakow, Poland.
700    1_
$a Tysarowski, Andrzej $u Centrum Onkologii Instytut im. Marii Sklodowskiej Curie, Warsaw, Poland.
700    1_
$a Barugel, Mario $u Tecnofarma, Santiago, Chile.
700    1_
$a van Krieken, J Han $u Radboud University Medical Center, Nijmegen, The Netherlands.
700    1_
$a Trojan, Jörg $u University Hospital, Frankfurt, Germany.
773    0_
$w MED00172897 $t Biomarkers in medicine $x 1752-0371 $g Roč. 11, č. 9 (2017), s. 751-760
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28747067 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190819121605 $b ABA008
999    __
$a ok $b bmc $g 1433920 $s 1067231
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 11 $c 9 $d 751-760 $e 20170727 $i 1752-0371 $m Biomarkers in medicine $n Biomark Med $x MED00172897
LZP    __
$a Pubmed-20190813
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace